个人中心 - 老虎社区

WengYongLi

Wander beyond the wilderness

IP属地：未知

帖子 · 175帖子 · 175
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- WengYongLiWengYongLi
  ·2021-12-24
  Pfizer will continue to soar short term. There are so little competition for vaccines.
  How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
  Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for
  How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
  1,607 1
  1
  分享
  举报
- WengYongLiWengYongLi
  ·2021-12-15
  Very insightful especially on crypto’s topic.
  非常抱歉，此主贴已删除
  1,785 1
  1
  分享
  举报
- WengYongLiWengYongLi
  ·2021-12-11
  Its more than what meets the headlines. China is always cautious. But good for long run
  非常抱歉，此主贴已删除
  2,171 1
  3
  分享
  举报
- WengYongLiWengYongLi
  ·2021-11-17
  Who cares what bofa says. They only care about their own bags
  Sea shares fell more than 7% in morning trading
  Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth. Bank of America analys
  Sea shares fell more than 7% in morning trading
  1,849 评论
  4
  分享
  举报
- WengYongLiWengYongLi
  ·2021-11-12
  Slow but sure
  2,006 评论
  4
  分享
  举报
- WengYongLiWengYongLi
  ·2021-11-10
  As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued
  非常抱歉，此主贴已删除
  2,245 1
  7
  分享
  举报
- WengYongLiWengYongLi
  ·2021-11-09
  $Iveda Solutions, Inc.(IVDA)$Up only
  1,826 评论
  1
  分享
  举报
- WengYongLiWengYongLi
  ·2021-11-07
  $Booking Holdings(BKNG)$This has been on meteoric rise. Once gantry all open, price goes up another 30%
  1,777 评论
  3
  分享
  举报
- WengYongLiWengYongLi
  ·2021-11-03
  $Iveda Solutions, Inc.(IVDA)$slow and sure
  1,983 评论
  3
  分享
  举报
- WengYongLiWengYongLi
  ·2021-10-20
  $4DS Memory(4DS.AU)$Hidden and suspended
  1,751 评论
  3
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574715322913604","uuid":"3574715322913604","gmtCreate":1611622781309,"gmtModify":1628260964620,"name":"WengYongLi","pinyin":"wengyongli","introduction":"","introductionEn":"","signature":"Wander beyond the wilderness","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":26,"headSize":134,"tweetSize":175,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":"80.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":698360236,"gmtCreate":1640306326685,"gmtModify":1640306391646,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"Pfizer will continue to soar short term. There are so little competition for vaccines.&nbsp;","listText":"Pfizer will continue to soar short term. There are so little competition for vaccines.&nbsp;","text":"Pfizer will continue to soar short term. There are so little competition for vaccines.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698360236","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-24 07:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607706537,"gmtCreate":1639583446503,"gmtModify":1639583446829,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"Very insightful especially on crypto’s topic.&nbsp;","listText":"Very insightful especially on crypto’s topic.&nbsp;","text":"Very insightful especially on crypto’s topic.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607706537","repostId":"2191956629","repostType":4,"isVote":1,"tweetType":1,"viewCount":1785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605510379,"gmtCreate":1639189290601,"gmtModify":1639189434109,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"Its more than what meets the headlines. China is always cautious. But good for long run","listText":"Its more than what meets the headlines. China is always cautious. But good for long run","text":"Its more than what meets the headlines. China is always cautious. But good for long run","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605510379","repostId":"2190275356","repostType":4,"isVote":1,"tweetType":1,"viewCount":2171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878809285,"gmtCreate":1637162516571,"gmtModify":1637162516688,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"Who cares what bofa says. They only care about their own bags","listText":"Who cares what bofa says. They only care about their own bags","text":"Who cares what bofa says. They only care about their own bags","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878809285","repostId":"1191602151","repostType":4,"repost":{"id":"1191602151","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637160729,"share":"https://www.laohu8.com/m/news/1191602151?lang=&edition=full","pubTime":"2021-11-17 22:52","market":"us","language":"en","title":"Sea shares fell more than 7% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1191602151","media":"Tiger Newspress","summary":"Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.\n\nBank of America analys","content":"<p>Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.</p>\n<p><img src=\"https://static.tigerbbs.com/4b220c8739f206a6f035287f0bc93429\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Bank of America analyst Sachin Salgaonkar downgrades the stock to a Neutral rating from a Buy.</p>\n<p>In addition, Sea&nbsp;kept gaming guidance unchanged, which implies slowing growth in Q4, Salgaonkar writes in a note to clients.</p>\n<p>The analyst sees a balanced risk/reward for the stock; shares&nbsp;climb 85%&nbsp;Y/Y.</p>\n<p>\"We cut our gaming revenue estimates to factor in a slowdown and increase e-com losses as we factor increasing cash-burn,\" the analyst notes.</p>\n<p>Lowers full-year 2022 loss per share estimate to $5.72 and 2023 to $4.45 per share.</p>\n<p>\"Consensus is yet to factor in rising losses in the medium term based on expansion into new markets in Europe/India.\"</p>\n<p>The Neutral rating agrees theNeutral Quant Rating, with the best factor grade in Momentum and the worst in Valuation.</p>\n<p>However, the Neutral rating diverges from the Very BullishWall Street Analyst Rating(18 Very Bullish, 7 Bullish).</p>\n<p>Previously, (June 10) Sea gotupgraded to Buy at BofA.</p>\n<p><img src=\"https://static.tigerbbs.com/6013b61a037fd78ec0a89cb8d3193ddc\" tg-width=\"726\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea shares fell more than 7% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea shares fell more than 7% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-17 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.</p>\n<p><img src=\"https://static.tigerbbs.com/4b220c8739f206a6f035287f0bc93429\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Bank of America analyst Sachin Salgaonkar downgrades the stock to a Neutral rating from a Buy.</p>\n<p>In addition, Sea&nbsp;kept gaming guidance unchanged, which implies slowing growth in Q4, Salgaonkar writes in a note to clients.</p>\n<p>The analyst sees a balanced risk/reward for the stock; shares&nbsp;climb 85%&nbsp;Y/Y.</p>\n<p>\"We cut our gaming revenue estimates to factor in a slowdown and increase e-com losses as we factor increasing cash-burn,\" the analyst notes.</p>\n<p>Lowers full-year 2022 loss per share estimate to $5.72 and 2023 to $4.45 per share.</p>\n<p>\"Consensus is yet to factor in rising losses in the medium term based on expansion into new markets in Europe/India.\"</p>\n<p>The Neutral rating agrees theNeutral Quant Rating, with the best factor grade in Momentum and the worst in Valuation.</p>\n<p>However, the Neutral rating diverges from the Very BullishWall Street Analyst Rating(18 Very Bullish, 7 Bullish).</p>\n<p>Previously, (June 10) Sea gotupgraded to Buy at BofA.</p>\n<p><img src=\"https://static.tigerbbs.com/6013b61a037fd78ec0a89cb8d3193ddc\" tg-width=\"726\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191602151","content_text":"Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.\n\nBank of America analyst Sachin Salgaonkar downgrades the stock to a Neutral rating from a Buy.\nIn addition, Sea kept gaming guidance unchanged, which implies slowing growth in Q4, Salgaonkar writes in a note to clients.\nThe analyst sees a balanced risk/reward for the stock; shares climb 85% Y/Y.\n\"We cut our gaming revenue estimates to factor in a slowdown and increase e-com losses as we factor increasing cash-burn,\" the analyst notes.\nLowers full-year 2022 loss per share estimate to $5.72 and 2023 to $4.45 per share.\n\"Consensus is yet to factor in rising losses in the medium term based on expansion into new markets in Europe/India.\"\nThe Neutral rating agrees theNeutral Quant Rating, with the best factor grade in Momentum and the worst in Valuation.\nHowever, the Neutral rating diverges from the Very BullishWall Street Analyst Rating(18 Very Bullish, 7 Bullish).\nPreviously, (June 10) Sea gotupgraded to Buy at BofA.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":1849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879950506,"gmtCreate":1636678186088,"gmtModify":1636678186503,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"Slow but sure","listText":"Slow but sure","text":"Slow but sure","images":[{"img":"https://static.tigerbbs.com/e52eefd34005572c21b56f1d61e84416","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879950506","isVote":1,"tweetType":1,"viewCount":2006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847953953,"gmtCreate":1636474166866,"gmtModify":1636474167230,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued","listText":"As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued","text":"As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847953953","repostId":"1127189501","repostType":2,"isVote":1,"tweetType":1,"viewCount":2245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844447839,"gmtCreate":1636455410265,"gmtModify":1636455410730,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>Up only","listText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>Up only","text":"$Iveda Solutions, Inc.(IVDA)$Up only","images":[{"img":"https://static.tigerbbs.com/bda88f3189c5fd0ed8a4f10f2f8daefb","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844447839","isVote":1,"tweetType":1,"viewCount":1826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845392318,"gmtCreate":1636278122906,"gmtModify":1636278123298,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BKNG\">$Booking Holdings(BKNG)$</a>This has been on meteoric rise. Once gantry all open, price goes up another 30%","listText":"<a href=\"https://laohu8.com/S/BKNG\">$Booking Holdings(BKNG)$</a>This has been on meteoric rise. Once gantry all open, price goes up another 30%","text":"$Booking Holdings(BKNG)$This has been on meteoric rise. Once gantry all open, price goes up another 30%","images":[{"img":"https://static.tigerbbs.com/11541445d326f24f9a97852cc9c2ff40","width":"1125","height":"3463"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845392318","isVote":1,"tweetType":1,"viewCount":1777,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841828036,"gmtCreate":1635902291749,"gmtModify":1635902291866,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>slow and sure","listText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>slow and sure","text":"$Iveda Solutions, Inc.(IVDA)$slow and sure","images":[{"img":"https://static.tigerbbs.com/246670e66a2812ef5bb140ace806b7e1","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841828036","isVote":1,"tweetType":1,"viewCount":1983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":859297292,"gmtCreate":1634697936966,"gmtModify":1634697998804,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574715322913604","authorIdStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/4DS.AU\">$4DS Memory(4DS.AU)$</a>Hidden and suspended","listText":"<a href=\"https://laohu8.com/S/4DS.AU\">$4DS Memory(4DS.AU)$</a>Hidden and suspended","text":"$4DS Memory(4DS.AU)$Hidden and suspended","images":[{"img":"https://static.tigerbbs.com/067201907e9d120e1588dcf17e2a73db","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859297292","isVote":1,"tweetType":1,"viewCount":1751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}